AI Article Synopsis
- The study explores the effectiveness of combining conjunctival rotational autograft (CRA) with 0.02% mitomycin C (MMC) for treating primary pterygium, aiming to assess its safety and recurrence rates.
- A total of 67 patients were observed over at least one year, revealing only 3% recurrence, significantly lower than MMC alone, suggesting CRA-MMC is more effective while also comparable to traditional autografts.
- The primary postoperative issue was cosmetic graft injection in 61% of cases, yet the procedure was deemed a safe alternative for patients where conventional grafting wasn't possible.
Article Abstract
Purpose: To describe the novel use of combined conjunctival rotational autograft (CRA) and intraoperative 0.02% mitomycin C (MMC) in the treatment of primary pterygium and to evaluate its safety and efficacy.
Methods: Prospective interventional case series comparing with historical controls was conducted. Patients with primary pterygium underwent pterygium excision, MMC was applied to the scleral bed after the surface conjunctiva was harvested, and the CRA was sutured back with a 180-degree rotation. Patients were followed for a minimum of 1 year.
Results: Sixty-seven eyes from 67 patients participated in the study, of which 31 (46.3%) were men and 36 (53.7%) were women. The mean age was 58 +/- 10.6 years, (range 36-79 years). There were 2 recurrences (3%), one occurring at month 3 and the other at month 9. Compared with historical controls, CRA-MMC resulted in significantly fewer recurrences than MMC alone (P = 0.005) when adjusted for age and was equally effective when compared with limbal-conjunctival autografts. The main postoperative problem was graft injection, which was noted in 41 eyes (61%) at 1 year.
Conclusions: To the best of our knowledge, this was the first study on the combined use of CRA and MMC in the treatment of primary pterygium. CRA with MMC was found to be effective in the prevention of recurrence. Although injection remained as a cosmetic concern, it was a safe alternative to limbal-conjunctival autograft in cases where mobilizing autologous conjunctival tissue would not be feasible.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICO.0b013e318187544d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibition of pterygium cell fibrosis by the Rho kinase inhibitor.
Sci Rep
December 2024
Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, RM305v, 1160 W. Michigan St., Indianapolis, IN, 46202, USA.
Pterygium is an ocular disease in which the conjunctival tissue invades the cornea. When the pterygium tissue reaches the pupillary region, the visual function of the patient is affected. Currently, surgical removal is the only effective treatment.
View Article and Find Full Text PDFComparison of Biomarkers Playing a Role in Pterygium Development in Pterygium and Recurrent Pterygium Tissues.
Diagnostics (Basel)
November 2024
Department of Medical Laboratory Techniques, Ataturk Vocational School of Health Services, Afyonkarahisar Health Sciences University, 03030 Afyonkarahisar, Turkey.
Pterygium is a nonneoplastic elastotic degeneration characterized by subepithelial growth. It manifests as an ocular lesion originating from the bulbar conjunctiva, extending to the corneal surface, and reaching the visual axis in some cases. Although the exact cause is unknown, prolonged exposure to ultraviolet radiation is considered the most significant contributing factor.
View Article and Find Full Text PDFSafety and efficacy of "hydro-fluorescein" technique in removing Tenon in pterygium surgery: a 1-year follow-up study.
Eye (Lond)
December 2024
Department of Ophthalmology, Kulliyyah of Medicine, International Islamic University Malaysia, Pahang, Malaysia.
Purpose: To assess the effectiveness and safety of the "hydro-fluorescein" adjunct technique for primary pterygium removal.
Design/methods: A non-randomized prospective study was conducted for various types of pterygium excision with superior bulbar conjunctival autograft (CAG) and fibrin glue. We introduced fluorescein staining to ensure thorough elimination of the Tenon tissue around the bare sclera area and the CAG.
In vivo confocal microscopy findings about ocular surface recovery in patients following pterygium excision combined with conjunctival autograft.
Int Ophthalmol
December 2024
Department of Ophthalmology, Jiangnan University Medical Center, Wuxi No.2 People's Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi, 214000, People's Republic of China.
Purpose: To study cellular and neural changes around the donor and recipient areas after pterygium excision combined with autologous conjunctival transplantation using corneal confocal microscopy, we evaluated the postoperative impact of this surgical procedure.
Methods: Patients with primary pterygium located on the nasal side who visited the Department of Ophthalmology of Wuxi Second People's Hospital between April and August 2023 were enrolled. Age-matched healthy eyes were included as the control group.
Evaluation of the clinical efficacy of modified LSC transplantation plus BCL implantation in the treatment of pterygium.
BMC Ophthalmol
December 2024
Department of Ophthalmology, Ziyang Central Hospital, Sichuan, 641300, China.
Objective: To explore the clinical efficacy of modified limbal stem cell transplantation(Modified LSC transplantation) and bandage contact lens(BCL) implantation in pterygium surgery.
Methods: A total of 479 patients with primary pterygium who were admitted to our hospital from March 2019 to March 2023 were randomly divided into three groups: the normal group (Group A: 89 patients), the control group (Group B: 195 patients), and the modified group (Group C: 195 patients). Each group received different intervention measures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!